Surface Oncology About Surface Oncology® We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. What Break Through Means to Us Surface Oncology is driven to deliver transformational outcomes for people with cancer who have no effective treatment options. We push ourselves to break through across all dimensions of our work by: Setting a high bar for potential patient impact at every stage of development Focusing on interrogating the most meaningful targets with proven technologies Leveraging multiple platforms to make fast decisions to benefit our overall portfolio Fostering an energetic and highly collaborative culture that emphasizes collective learning Leadership Our leaders and advisors drive the bold pursuit of transformative cancer care. Management Team Scientific Advisory Board Board of Directors Robert Ross, M.D. Chief Executive Officer Chandra Adams VP, Legal Shannon Rourke Devens VP, Clinical Development Operations Jessica Fees Chief Financial Officer Benjamin Lee, M.D., Ph.D. VP, Translational Science Lisa McGrath SVP, Human Resources Liisa I. Nogelo Chief Legal Officer Alison O’Neill, M.D. Chief Medical Officer Vito Palombella, Ph.D. Chief Scientific Officer Henry Rath Chief Business Officer Pushing Further with Partners To break through the current boundaries of medical science, collaborations are a crucial part of our strategy. Surface has entered into two strategic collaborations to advance our next-generation cancer therapies. In January 2016, Surface entered into an agreement with Novartis to exclusively license worldwide rights to NZV930 (formerly SRF373), Surface’s fully human CD73 antibody. Surface received an upfront payment of $70 million from Novartis and is entitled to potential milestone payments upon the achievement of specified development and sales milestones of $525 million, as well as tiered royalties. In December 2020, Surface entered into an agreement with GSK to exclusively license worldwide rights to SRF813, Surface’s fully human CD112R antibody. Surface received an upfront payment of $85 million from GSK and is entitled to an additional $730 million in future milestone payments, as well as tiered royalties on global net sales. Are you interested in partnering with Surface? Please contact us at partner@surfaceoncology.com. Surface Oncology © 2021 Surface Oncology SURFACE ONCOLOGY and the Surface Oncology logo are registered trademarks of Surface Oncology, Inc. All rights reserved. 50 Hampshire Street, 8th Floor Cambridge, MA 02139 Privacy Terms of Use Twitter Community Guidelines Connect with Surface Twitter LinkedIn Instagram Glassdoor Home About Us Pipeline & Programs Investors & Media Life Under the Surface Contact